Department of Neurology, Oslo University Hospital, Oslo, Norway.
Department of Neurology, Oslo University Hospital, Oslo, Norway.
Seizure. 2018 Oct;61:111-118. doi: 10.1016/j.seizure.2018.07.020. Epub 2018 Jul 29.
Several multinational prospective registers have shown that a significant proportion of status epilepticus (SE) patients are not treated in line with international guidelines. The aim of this study was to assess quality of treatment and to identify factors associated with refractoriness and outcome in a cohort of adult SE patients in Norway.
151 patients treated in Oslo University Hospital from 2001 to 2017 were included. One SE-episode was selected per patient and variables related to the patient, SE-episode, treatment and outcome entered into a database. Status Epilepticus Severity Score (STESS) and Epidemiology-based Mortality Score in SE (EMSE) were calculated for each episode.
68% (n = 102) of SE-episodes were responsive, 20% (n = 30) refractory and 12% (n = 19) superrefractory. Mortality was 9%, with a significant difference between responsive episodes (1%) and refractory (superrefractory included) episodes (24%), p < 0.001. 86% of patients received a benzodiazepine as 1st antiepileptic drug. Multivariate analysis showed that non-convulsive SE in coma was significantly associated with refractoriness (p = 0.04), while focal non-convulsive SE without coma was associated with responsiveness (p = 0.03). Younger age was associated with superrefractoriness (p = 0.02). Regarding outcome, EMSE-EtiologyAgeComorbiditiesEEG (EACE)≥64 (p = 0.02) and use of vasopressors (p = 0.03) were associated with a worsening of the modified Rankin scale at discharge. STESS was only associated with outcome in univariate analysis.
In this cohort in which international guidelines for treatment of SE were well followed, semiology of the SE was found to be the most important determinant of refractoriness, and the new clinical scoring system EMSE-EACE was robustly associated with outcome.
几项多中心前瞻性登记研究表明,相当一部分癫痫持续状态(SE)患者的治疗不符合国际指南。本研究的目的是评估挪威一组成年 SE 患者的治疗质量,并确定与难治性和结局相关的因素。
纳入了 2001 年至 2017 年在奥斯陆大学医院治疗的 151 名患者。每位患者选择一个 SE 发作,将与患者、SE 发作、治疗和结局相关的变量输入数据库。为每个发作计算癫痫持续状态严重程度评分(STESS)和基于流行病学的 SE 死亡率评分(EMSE)。
68%(n=102)的 SE 发作有反应,20%(n=30)为难治性,12%(n=19)为超难治性。死亡率为 9%,有反应发作(1%)和难治性(包括超难治性)发作(24%)之间存在显著差异,p<0.001。86%的患者接受苯二氮䓬类药物作为一线抗癫痫药物。多变量分析显示,昏迷中的非惊厥性 SE 与难治性显著相关(p=0.04),而无昏迷的局灶性非惊厥性 SE 与反应性相关(p=0.03)。年龄较小与超难治性相关(p=0.02)。关于结局,EACE 评分≥64(p=0.02)和使用血管加压素(p=0.03)与出院时改良 Rankin 量表评分恶化相关。STESS 仅在单变量分析中与结局相关。
在本研究中,SE 的治疗遵循了国际指南,SE 的临床表现是难治性的最重要决定因素,新的临床评分系统 EMSE-EACE 与结局密切相关。